… In Itchy E3 ubiquitin protein ligase homolog (ITCH), for example, it is the WW domains that
bind to the HECT domain, whereas in SMURF2, both the C2 and WW1 domains are required […

… and identifying novel molecular therapeutic targets for patients with CRC are still key issues.
… 2), these enzymes represent attractive therapeutic targets. Some molecules have been …

… that the HECT and RLD domains containing E3 ubiquitin protein ligase 3 (HERC3) could
directly … mediate ERK2 and p53 signaling, which offers new potential targets for clinical therapy. …

Therapy resistance is still a major reason for treatment failure in colorectal cancer (CRC).
Previously, we identified the E3 ubiquitin ligase TRIM25 as a novel suppressor of caspase-2 …

… In summary, this paper highlights the potential value of TRIM27 as a novel therapeutic target
particularly for treatment of inflammation-associated cancer [65]. Similar to TRIM27, TRIM29 …

These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its
control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner. …

… ubiquitin onto its target substrate, which is critical in … specific drug target for a certain
immunological response … HECT and RLD domain containing E3 ubiquitin protein ligase 2…

… Previously, we reported that loss of HERC5 (HECT and RLD domain containing E3
ubiquitin protein ligase 5) in non-small cell lung cancer (NSCLC) patients leads to a positive …

Interferon (IFN) activity exhibits a gender bias in human skin, skewed toward females. We
show that HERC6, an IFN-induced E3 ubiquitin ligase, is induced in human keratinocytes …

… a potential therapeutic target. However, a phase I clinical trial using a monoclonal antibody
against IFNα did not show clinical benefits among patients with chronic plaque psoriasis (57). …